Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries.
Peter C TaylorYuri Sanchez GonzalezRyan ClarkFreddy FaccinOliver HowellPublished in: Rheumatology and therapy (2023)
Non-medical switching in RA treatment may lead to unforeseen outcomes that should be considered by health decision-makers.
Keyphrases
- healthcare
- rheumatoid arthritis
- public health
- primary care
- electronic health record
- health information
- disease activity
- juvenile idiopathic arthritis
- ankylosing spondylitis
- type diabetes
- adipose tissue
- decision making
- machine learning
- climate change
- human health
- idiopathic pulmonary fibrosis
- interstitial lung disease
- hidradenitis suppurativa
- replacement therapy